You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

221 Results
Guidelines and Advice
Status: Current
ID: ES PET 20
Apr 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Head and Neck, 
Salivary Gland
Intent: Palliative
Jul 2022
Drug
Other Name(s): Tepadina®
Jan 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Nov 2024
Drug
Other Name(s): Kimmtrak®
Oct 2025
Drug
Other Name(s): Imjudo®
Apr 2024
Document
Jun 2024
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Feb 2025

Pages